- Home
- ABVC vs KLRS Comparison
ABVC vs KLRS Comparison
Compare ABVC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABVC | KLRS |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5M | 46.0M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABVC | KLRS |
|---|---|---|
| Price | $1.34 | $9.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | 57.2K | ★ 58.1K |
| Earning Date | 06-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $509,589.00 | N/A |
| Revenue This Year | $735.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $2.14 |
| 52 Week High | $4.02 | $11.90 |
Technical Indicators
Market Signals| Indicator | ABVC | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 32.44 | 51.11 |
| Support Level | $1.15 | $8.08 |
| Resistance Level | $1.52 | $10.64 |
| Average True Range (ATR) | 0.11 | 1.05 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 30.34 | 55.18 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.